Lauren Folino

Lauren Folino

Most Recent Articles by Lauren Folino

Companies react to Facebook's open walls

After Facebook's decision on August 15 to enforce open walls on the site's pharma pages, companies had two options: close down their pages altogether, or let the public openly comment on their products.

ImpactRx's TabletImpact shows reps tablet's strengths

ImpactRx, a firm that measures the impact of promotional materials on physician prescribing behavior, has launched TabletImpact, an analytical tool for pharma sales representatives.

KnowledgePoint360 launches "My Virtual How" to aid health pub professionals

Healthcare communications network KnowledgePoint360 has expanded its roster of health strategy tools to include "My Virtual How" (MyVHow), a management tool designed to benchmark best practices in the development of medical publications.

LEO Pharma grows its sales division

LEO Pharma, Inc., a wholly owned US subsidiary of the 100-year old Danish organization LEO Pharma A/S, has reported growth of 85% in the overall sales force associated with the company since it officially launched in January 2010.

Manilow helps 'Get Back in Rhythm' target AFib

Sanofi US has teamed up with crooner Barry Manilow in kicking off a national awareness campaign for atrial fibrillation (AFib) called "Get Back in Rhythm."

More Articles by Lauren Folino

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.